Author response to: OSIN-D-24-01586, "Revisiting the safety of romosozumab in Japan: the need for clear contraindications for patients with cardiovascular risk"

Osteoporos Int. 2025 Jan 8. doi: 10.1007/s00198-024-07348-2. Online ahead of print.

Authors

Soichiro Masuda^{1

2}, Toshiki Fukasawa², Shuichi Matsuda³, Satomi Yoshida², Koji Kawakami⁴

Affiliations

¹ Department of Orthopedic Surgery, Kyoto City Hospital, Kyoto, Japan.
² Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
³ Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁴ Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. [email protected].

PMID: 39777490
DOI: 10.1007/s00198-024-07348-2

No abstract available

Publication types

Letter